logo
  

AbbVie Receives Option To License Certain IL-2 Muteins, Including CUG252, From Cugene

AbbVie (ABBV) and Cugene Inc. announced a worldwide license option agreement for CUG252, a potential Treg-selective IL-2 mutein, as well as other IL-2 muteins, for the potential treatment of autoimmune and inflammatory diseases. During the option period, Cugene will conduct a phase 1b study in patients with autoimmune/inflammatory disease. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing and commercialization activities for CUG252.

Cugene will receive an upfront payment of $48.5 million, and will also be eligible to receive development and regulatory milestones and a license option exercise payment if AbbVie exercises the option. Also, Cugene may receive commercialization and sales-based milestones and tiered royalties.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sysco Corp. (SYY) Tuesday reported a more than a three-times surge in fourth-quarter earnings, supported by 17.5 percent growth in sales. The company projects fiscal 2023 adjusted earnings to grow. Earnings for the quarter spiked to $509.99 million from $151.09 million last year. On a per share basis,... Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly...
Follow RTT